John Militello - 11 Feb 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for John Militello
Issuer symbol: RCKT
Transactions as of: 11 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Feb 2026, 16:05:27 UTC
Previous filing: 20 Nov 2025
Next filing: 18 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Militello John	Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY	/s/ Martin Wilson, as attorney-in-fact for John Militello	13 Feb 2026	0001662170

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock	Award	$0	+29,982	+45%	$0.000000	95,902	11 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Stock Option (Right to Buy)	Award	$0	+45,018		$0.000000	45,018	11 Feb 2026	Common Stock	45,018	$3.24	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2	Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
F3	This option represents a right to purchase a total of 45,018 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.